Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660878 | 1.00 | POLB (0.70) | POLBALDH1A1HPGDMAPK1KEAP1 | |
| SCHEMBL12793683 | 0.87 | POLB (0.72) | POLBALDH1A1HPGDMAPK1HTR2C | |
| SCHEMBL5960083 | 0.87 | KMT2A (0.72) | POLBALDH1A1HPGDMAPK1HTR2C | |
| SCHEMBL28113175 | 0.87 | POLB (0.68) | POLBALDH1A1HPGDMAPK1HTR2C | |
| SCHEMBL29540801 | 0.87 | KEAP1 (0.70) | POLBALDH1A1HPGDKEAP1KMT2A | |
| SCHEMBL11728730 | 0.82 | ALDH1A1 (0.65) | POLBALDH1A1HPGDMAPK1HTR2C | |
| SCHEMBL5598318 | 0.81 | POLB (0.60) | POLBALDH1A1HPGDMAPK1HTR2C | |
| SCHEMBL12792956 | 0.80 | MEN1 (0.60) | POLBALDH1A1HPGDMAPK1HTR2C | |
| SCHEMBL10782659 | 0.79 | KEAP1 (0.59) | ALDH1A1KEAP1KMT2AMEN1MCL1 | |
| SCHEMBL4661660 | 0.79 | MEN1 (0.81) | POLBALDH1A1HPGDKEAP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112645852-B | Synthesis method for catalyzing reduction of imine into amine | 赣南医学院 | 2022-06-14 | — | — | CN | disclosed |
| CN-112645852-A | Synthesis method for catalyzing reduction of imine into amine | 赣南医学院 | 2021-04-13 | — | — | CN | disclosed |
| EP-2007760-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007108569-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-09-27 | — | — | WO | disclosed |
| US-7049468-B2 | Modulators of Rho C activity | ICONIX PHARMACEUTICALS, INC. (US) | 2006-05-23 | — | — | US | disclosed |
| EP-1453470-A4 | MODULATORS OF RHO C ACTIVITY | ICONIX PHARM INC (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1453470-A1 | MODULATORS OF RHO C ACTIVITY | Iconix Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030171341-A1 | Method for modulating the activity of a Rho C enzyme, comprising: contacting said Rho C enzyme with an effective amount of a compound of formula 1: | ENTELOS HOLDING CORP. | 2003-09-11 | — | — | US | disclosed |
| WO-2003043578-A2 | MODULATORS OF RHO C ACTIVITY | ICONIX PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171341-A1 | Method for modulating the activity of a Rho C enzyme, comprising: contacting said Rho C enzyme with an effective amount of a compound of formula 1: | RHOC, RHOA, ROCK1 | POLB 2202/4885ALDH1A1 1730/4885HPGD 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.